Opioid use disorder; require substance use disorder facilities to provide pregnant women with onsite access to certain treatments.

HB 718 would require Mississippi substance use disorder facilities treating pregnant women with opioid use disorder to provide onsite access to at least one FDA-approved medication treatment (like methadone or buprenorphine). It directly affects pregnant women seeking treatment and facilities certified by the State Department of Mental Health. The bill mandates facilities to submit compliance attestations by 2026 and requires the Department to monitor adherence and report annually to health committees on treatment access. However, the bill died in committee on February 4, 2025, so it has not become law.